IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Aggregated presentation by day and by market
| Statement of transactions in own shares from June 3 to June 7, 2024 | ||||||
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 03/06/2024 | FR0010259150 | 3 100 | 120,9943 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/06/2024 | FR0010259150 | 3 100 | 121,5713 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/06/2024 | FR0010259150 | 3 100 | 122,2187 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/06/2024 | FR0010259150 | 3 500 | 122,5593 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/06/2024 | FR0010259150 | 5 000 | 123,1718 | XPAR |
| TOTAL | 17 800 | 122,2274 | ||||
| 17 800 | ||||||
Attachment
14 October 2024
1 mins read
Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
29 June 2022
1 mins read
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
01 June 2021
1 mins read
Ipsen announces the launch of an Employee Shareholding Plan